cover image European Journal of Neurology

European Journal of Neurology

2025 - Volume 32
Issue 8 | August 2025

ISSUE INFORMATION

Issue Information

ORIGINAL ARTICLE

Background

The “insular knife‐cut” sign is a sharp demarcation between hyperintense insular lesions on fluid‐attenuated inversion recovery axial images and the basal ganglia, detected on brain MRI. This sign has been associated with herpes simplex virus encephalitis (HSVE); however, its specificity remains unknown. We assessed the frequency and specificity of the insular knife‐cut sign in a real‐life cohort of patients with suspected HSVE.

Methods

We retrospectively identified patients admitted for suspected HSVE over the past 10 years at three Neurology Units in Italy. Inclusion criteria were cerebrospinal fluid (CSF) tested for HSV‐1/2 PCR and acute brain MRI available.

Results

A total of 188 patients were included: HSVE, 44; alternative diagnoses, 144 (autoimmune encephalitis, 51; infectious encephalitis, 22; other acute encephalopathies, 71). The insular knife‐cut sign was present on the initial brain MRI in 23/44 (52.3%) HSVE patients and 1/144 (0.7%) patients with alternative diagnoses ( < 0.001). The specificity and sensitivity of the sign were 99.3% (95% CI, 96–100) and 52% (95% CI, 38–66), respectively. In eight HSVE patients, the insular knife‐cut sign appeared on subsequent MRIs obtained acutely, raising the sensitivity to 70.5% (95% CI, 56–82). On multivariate regression, the insular knife‐cut sign was the strongest independent predictor (odds ratio [95% CI]) of HSVE (68.9 [11.42–415.54]), followed by temporal pole involvement (8.44 [2.06–34.6]), and CSF pleocytosis (6 [1.7–21.18]).

Conclusions

In patients with suspected encephalitis, the insular knife‐cut sign on MRI strongly predicts a diagnosis of HSVE. Its detection should prompt consideration of HSVE, even when other diagnostic tests are equivocal/unavailable.

ORIGINAL ARTICLE

Objective

To evaluate the cost‐effectiveness and cost–utility of adding ultra‐early and short‐term administration of tranexamic acid (TXA) to standard care in patients with subarachnoid hemorrhage (SAH).

Materials and Methods

An economic evaluation was performed alongside the ultra‐early tranexamic acid after subarachnoid hemorrhage (ULTRA) trial. The main outcomes were the incremental cost‐effectiveness ratio (ICER), expressed as costs per one‐point increase in modified Rankin scale (mRS) score, and the incremental cost–utility ratio (ICUR), expressed as costs per quality‐adjusted life‐year (QALY). Cost‐effectiveness acceptability curves (CEACs) were visualized with varying ICER cut‐offs. Bootstrapping techniques and sensitivity analyses were performed to account for uncertainty.

Results

The ULTRA trial included 955 patients, with 480 assigned to the TXA group and 475 to the control group. The mean mRS score was 3.4 (95% CI: 3.2–3.5) in the TXA group and 3.2 (95% CI: 3.0–3.4) in the control group. The mean QALY was 0.26 (95% CI: 0.24–0.28) in the TXA group and 0.28 (95% CI: 0.26–0.30) in the control group. Mean costs were €62,180 (95% CI: 57,589–66,913) in the TXA group and €58,624 (95% CI: 53,693–63,955) in the control group. The probability of treatment with TXA being cost‐effective ranged from 4% to 16% for mRS and from 8% to 16% for QALYs.

Conclusions

Ultra‐early and short‐term administration of TXA to patients with SAH is not cost‐effective. Therefore, we recommend against using TXA for this patient group.

CASE REPORT

Objectives

To report a case of a novel variant of the gene associated with Cerebral Amyloid Angiopathy (CAA), thereby expanding the spectrum of TTR‐related amyloidosis.

Methods

A 56‐year‐old man presented with a history of right fronto‐parietal intracerebral haemorrhage and recurrent transient episodes of right arm paraesthesia. Based on clinical and radiological presentation, a probable CAA diagnosis was established according to Boston Criteria 2.0. The patient underwent an extensive evaluation, including genetic testing, cerebrospinal fluid (CSF) analysis and amyloid PET imaging.

Results

CSF analysis and amyloid PET imaging corroborated CAA diagnosis. Genetic testing identified an undescribed heterozygous c.124G > A (p.Gly42Ser) variant, absent from population databases, within a region known for pathogenic mutations. Family genetic testing revealed the same mutation in the patient's father, who had a history of cerebral haemorrhage.

Discussion

To our knowledge, this case represents one of the first documented examples of a gene variant exclusively associated with CAA, in the absence of systemic amyloidosis. These findings suggest the existence of variants that may result in a brain‐restricted amyloid pathology. Genetic screening for mutations should be considered in familial cases of CAA to refine diagnostic accuracy and guide clinical management strategies.

ORIGINAL ARTICLE

Background

In the Phase 3 MycarinG study (NCT03971422), rozanolixizumab improved myasthenia gravis (MG)‐specific outcomes versus placebo in patients with generalised MG, including those measured by the five independent MG Symptoms patient‐reported outcome (PRO) scales: Muscle Weakness Fatigability (MWF), Physical Fatigue (PF) and Bulbar Muscle Weakness (BMW) as secondary endpoints and Ocular Muscle Weakness and Respiratory Muscle Weakness (exploratory endpoints). This research aimed to provide further insights into these improvements.

Methods

analyses evaluated correlation (Pearson coefficient) between MG Symptoms PRO and subdomain scores of MG Activities of Daily Living (MG‐ADL) and Quantitative MG (QMG) at baseline. Proportions of responders reaching clinically meaningful thresholds and analyses at the item level (observed mean change and Rasch modelling of predicted change from baseline) are reported for MWF, PF, and BMW with rozanolixizumab versus placebo at Day 43.

Results

Correlation coefficients between MG Symptoms PRO and MG‐ADL were strong (≥ 0.7) for ocular and bulbar scores and moderate (0.5 to < 0.7) for other scores. Correlations with clinician‐assessed QMG scores were generally weak (< 0.5). For MWF, PF, and BMW, greater proportions of responders were observed with rozanolixizumab 7 mg/kg (46.9%, 31.3% and 26.6%, respectively) or 10 mg/kg (56.5%, 48.4% and 32.3%) versus placebo (28.1%, 26.6% and 10.9%). Item‐level analyses demonstrated rozanolixizumab benefit at a symptom‐specific level.

Discussion

MG Symptoms PRO scales correlate well with concepts in MG‐ADL while assessing additional concepts, such as PF and MWF. Results from the MG Symptoms PRO in MycarinG reflected improvements from baseline in patient‐relevant symptoms, including fatigue, with rozanolixizumab.

ORIGINAL ARTICLE

Introduction

Spontaneous intracranial hypotension (SIH) is an important cause of headache that might require invasive treatment. The aim of this study was to systematically investigate (1) clinical presentation, (2) factors associated with incomplete headache resolution, and (3) the long‐term outcomes in patients with persistent headache after invasive treatment for SIH.

Methods

This is an observational longitudinal study. We used a structured questionnaire to assess details on primary headache, SIH‐headache, and headache after treatment. Persistent headache was defined as headache on more than 15 days per month lasting longer than 3 months.

Results

Fifty‐six patients invasively treated for SIH were included in the study. The mean age was 49 ± 12 years, and 60% were women. After sealing of the leak, 11/56 (20%) had persistent headache. Compared to subjects without persistent headache, patients with persistent headache had been treated after a longer delay from SIH symptom onset (362 days [IQR 138–714] vs. 111 [68–365]). In 2/11 (18%) patients, a second leak at another level and rebound intracranial hypertension were found, respectively. Medication overuse was reported by 3/11 (27%) patients. After a median follow‐up of 5 years, headache subsided completely in 4/11 (36%) patients and improved in 4/11 (36%).

Conclusion

In our cohort, one fifth of patients suffered from persistent headache despite successful sealing of the CSF leak. Although the majority of patients showed improvement in the long run, important secondary headaches should be considered, namely medication overuse, rebound hypertension, and a persistent, reopened, de novo or second leak at another level.

ORIGINAL ARTICLE

Objective

To assess changes in the facioscapulohumeral muscular dystrophy Rasch‐Built Overall Disability Scale (FSHD‐RODS) over 6.5 years in FSHD patients.

Methods

FSHD patients of 18 years or older were assessed at baseline (T1) and followed up at 5 years (T2) and 6.5 years (T3). The patient‐reported FSHD‐RODS and Sickness Impact Profile 68 (SIP68) questionnaires were evaluated, alongside the FSHD clinical severity score, FSHD clinical score and Motor Function Measure (MFM). Individual minimal clinically important differences (MCID‐SE) of the FSHD‐RODS were calculated to assess the clinical importance of the change over time. A subgroup analysis included patients eligible for current clinical trials.

Results

Sixty‐two patients were included, representing the full disease spectrum. The FSHD‐RODS and SIP68 questionnaire outcomes remained stable, whereas overall disease severity slightly increased (FSHD clinical severity score 6 to 6.5,  < 0.001) and MFM slightly decreased (94% to 91%,  < 0.001). FSHD‐RODS correlated strongly with SIP68, MFM and disease severity ( ≥ 0.69). The clinical trial subgroup ( = 33) showed similar results. Ten patients (16%), all with moderate–to‐severe baseline disease (FSHD clinical severity score ≥ 6), showed clinically important deterioration over 6.5 years.

Conclusions

FSHD progression is generally slow, with FSHD‐RODS only detecting meaningful decline in moderately to severely affected patients. The ability to compensate for muscle weakness may limit the sensitivity of patient‐reported outcomes like FSHD‐RODS in clinical trials. These findings highlight the need for alternative measures to capture disease progression and treatment effects in FSHD research.

CORRIGENDUM

Correction to “Association Between CD20+ T Lymphocytes and Neuropsychological Findings in Multiple Sclerosis”

ORIGINAL ARTICLE

Background

Autoimmune encephalitis (AE) is a severe neurological disorder that requires effective and safe treatment options. This study aimed to compare the efficacy and safety of intravenous methylprednisolone (IVMP) plus efgartigimod (IPE) versus IVMP alone or IVMP plus immunoglobulin (IPI) as initial treatments for antibody‐mediated AE.

Methods

A retrospective, single‐center, cross‐sectional study was conducted to compare treatment responses between the IPE group and the IVMP or IPI groups at baseline and after 2, 4, 8, and 12 weeks. Responses were assessed using the Clinical Assessment Scale (CASE) and modified Rankin Scale (mRS) scores, with propensity score matching (PSM) applied to adjust for confounding variables.

Results

A total of 122 patients with surface antibody‐mediated AE were included. After 1:1 PSM, 16 pairs (IPE vs. IVMP) and 15 pairs (IPE vs. IPI) were matched. At 2 weeks post‐treatment, the IPE group demonstrated significantly greater improvements in CASE scores from baseline (ΔCASE: 6.5 [IQR = 3.3–8.8] vs. 3.0 [0.0–6.0]) and mRS scores from baseline (ΔmRS: 1.5 [1.0–2.0] vs. 1.0 [0.0–1.0]) compared to the IVMP group, along with a higher proportion of favorable outcomes (mRS ≤ 2: 75.0% vs. 20.0%). No significant differences in CASE or mRS score changes were observed between the IPE and IPI groups over the 12‐week follow‐up period. Only one mild case of facial rash was reported during efgartigimod treatment, which resolved promptly.

Conclusions

Efgartigimod, when added to IVMP treatment, demonstrates rapid efficacy and favorable safety in antibody‐positive AE. These findings suggest the need for further investigation in larger clinical trials.

CASE REPORT

Objectives

The differential diagnosis of functional and other etiologies of dystonia can be difficult. We performed a clinical neurophysiological study in a female patient with cranial–cervical dystonia, providing strong evidence for the diagnosis of functional dystonia.

Methods

The patient had torticollis and intermittent facial pulling with downward deviation of the left angle of the mouth. She had left laterocollis and right torticollis with left shoulder elevation. She additionally experienced limited anterior–posterior flexion of the neck and moderate limitation of lateral flexion and neck rotation in both directions without spinal cord compression. We recorded abnormal discrete movements of the lower lip with surface electromyography (EMG). Electroencephalography was recorded simultaneously to identify a possible Bereitschaftspotential (BP) before the abnormal movement. We also tested inhibition of the blink reflex and pre‐pulse inhibition (PPI) using supraorbital nerve stimulation with a conditioning‐test paired‐pulse paradigm.

Results

The EMG of the dystonic left lip movements varied in shape, duration, and amplitude. A BP was observed before the abnormal lip movement. The topographic distribution of BP with abnormal lip movement was similar to that with voluntarily mimicked lip movement and with voluntary movement of arm extension. The R2 component of the blink reflex was inhibited with a preceding conditioning pulse at interstimulus intervals of 150–1000 ms. Significant PPI was found at intervals of 60–120 ms. The R1 component of the blink reflex was not inhibited.

Discussion

The patient has functional dystonia. Our results suggest that in some circumstances clinical neurophysiological tests can support the differential diagnosis of functional cranial–cervical dystonia.

REVIEW ARTICLE

Background

Botulinum neurotoxin A (BoNT‐A) is recommended for the treatment of cervical dystonia (CD), spasticity, and blepharospasm. Some patients treated with BoNT‐A have been reported to develop neutralizing antibodies (NAbs) against BoNT‐A, which may result in reduced efficacy and, in some cases, secondary treatment failure (STF). Our aim was to investigate the incidence of STF and NAb positivity after treatment with one of three commercially‐available BoNT‐A formulations.

Methods

A systematic review and meta‐analysis of STF and/or NAb positivity after treatment with abobotulinumtoxinA, incobotulinumtoxinA, or onabotulinumtoxinA in patients with CD, spasticity, or blepharospasm was conducted using PubMed, Embase, and Google Scholar.

Results

Twenty‐nine unique studies reported in 29 publications assessed NAb positivity and were included. The meta‐analysis showed that the proportions of patients developing STF were significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. Depending on the antibody test used, the proportions of patients developing NAbs were also significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. When data for all indications were pooled, proportions of NAb‐positive patients were numerically higher with increasing mean doses of abobotulinumtoxinA or onabotulinumtoxinA. No patients treated exclusively with incobotulinumtoxinA were found to have developed immunogenic STF or persistent NAbs.

Conclusions

The risk of developing STF and NAbs appears to vary with indication and BoNT‐A formulation. When the efficacy and safety of formulations are comparable, incobotulinumtoxinA may be recommended to avoid developing STF and immunogenicity, particularly for patients requiring higher doses and repeated treatments.

ORIGINAL ARTICLE

Introduction

The extent of peripheral nerve involvement in inclusion body myositis (IBM) remains a topic of ongoing scientific discussion. In this study, we aimed to explore the involvement of small nerve fibers in IBM using a range of diagnostic methods, including, for the first time, corneal confocal microscopy (CCM).

Methods

Nineteen clinic‐pathologically or clinically defined IBM patients underwent comprehensive clinical and electrophysiological examinations. A multimodal small fiber examination was performed, including a skin biopsy of the thigh and lower leg, quantitative sensory testing of the feet, and CCM. Pain levels and quality of life were also assessed using standardized questionnaires (Small Fiber Neuropathy Screening List, PainDETECT, Brief Pain Inventory, Short Form‐36).

Results

The motor and sensory neurography identified large fiber neuropathy in 67% of cases. Regarding small fibers evaluation, skin biopsy revealed pathological findings in 72% of cases and CCM in 32% of cases. Quantitative sensory testing results predominantly indicated large fiber damage (61%), with small fiber pathology identified in only 12% of cases. Questionnaire responses suggested a slight pain‐related impact on patients' quality of life.

Discussion

Small nerve fiber pathology is a frequent finding in skin biopsies of IBM patients. However, noninvasive methods like CCM appear less sensitive than skin biopsy for diagnosing small fiber pathology in IBM patients. Further studies are needed to refine diagnostic approaches and better understand the role of small fiber involvement in IBM.

ORIGINAL ARTICLE

Background

Hereditary polyneuropathy is a disabling condition with a genetic aetiology. However, genetic confirmation is not always attainable. This study aimed to assess the diagnostic clarification rate achieved through reassessment, including whole genome sequencing (WGS), in patients without confirmed genetic diagnoses.

Methods

We conducted a cross‐sectional study using diagnosis codes to identify patients with hereditary polyneuropathy at a specialized neuromuscular center. Clinically diagnosed patients without genetic confirmation were invited to participate. They underwent neurological examination, composite scoring, extensive blood testing, and WGS. Based on the reassessment, patients were stratified into three groups: (1) genetic findings, (2) non‐genetic aetiologies, and (3) no identified aetiology.

Results

We screened 386 patient records; 66 patients were eligible, and 44 were included. Mean age at inclusion was 52.7 years, and mean age at symptom onset was 31.2 years. Reassessment identified six non‐genetic etiologies, including treatable causes such as disc protrusion, systemic lupus, and chronic inflammatory demyelinating polyneuropathy. A relevant genetic variant was identified in 13 out of the 44 patients, yielding a genetic clarification rate of 30%. The most frequent genetic variant was the homozygous c.757del variant in , found exclusively in patients with axonal neuropathy and teenage onset.

Conclusions

Reassessment clarified the diagnosis in 44% of clinically diagnosed patients with hereditary polyneuropathy (30% genetic, 14% non‐genetic), underscoring the potential of reassessment in improving diagnostic precision.

ORIGINAL ARTICLE

Rationale

Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease in which genetics plays a central role for both familial and sporadic ALS cases. Systematic genetic analysis for all ALS patients is recommended at the time of diagnosis, leading to an early proposal of specific genetic therapy. Currently, is considered the most frequently mutated gene in ALS. Patients with a pathogenic or probably pathogenic variants (ACMG classification) are eligible for antisense oligonucleotide therapy.

Objective

To determine the frequency of variants and G4C2 repeats in a French ALS population and to describe genotype–phenotype relationships.

Material and Methods

One thousand incident ALS patients were enrolled from 22 ALS centers in France and followed up for 12 months. Epidemiological, familial history, neurological data, and genetic status were collected.

Main Results

G4C2 repeats and variants were observed in 7.6% and 1.6%, respectively. Fifty percent of patients and 51% of patients had sporadic ALS. Fifteen different variants were identified within the five exons and one intron. patients had a significantly younger age at onset and a trend toward a faster progression compared to non‐expanded patients. Moreover, among the non non population, patients with at least one copy with two G4C2 repeats had a shorter disease duration.

Conclusion

This study confirms variants low frequency in the French population and highlights the more rapid disease progression observed in patients carrying expansions. These findings underscore the importance of systematic genetic screening at diagnosis.

ORIGINAL ARTICLE

Background and Objectives

Immune effector cell‐associated neurotoxicity syndrome (ICANS) is a potential complication following Chimeric Antigen Receptor (CAR) T‐cell infusion. Biomarkers to aid in early diagnosis and severity assessment are lacking. We aim to describe and compare serum neurofilament light chain (sNfL) dynamics in non‐Hodgkin lymphoma (NHL) patients undergoing anti‐CD19 CAR T‐cell therapy, based on ICANS presence and severity.

Methods

This is a case–control study nested within a cohort of NHL patients treated with anti‐CD19 CAR T‐cells at a tertiary care center. From this cohort, we selected those who developed ICANS and had available blood samples. These patients were compared to matched NHL patients without ICANS from the same cohort. sNfL concentrations were measured immediately pre‐infusion and on days 7 and 14 post‐infusion, with ‐scores calculated against a normative database. Mixed linear and ROC analysis assessed sNfL dynamics by ICANS presence and severity.

Results

Of 159 patients treated, 54 (34%) developed ICANS. We included 32 patients with ICANS and 22 matched controls. Baseline sNfL concentrations were similarly elevated in both ICANS and non‐ICANS patients. However, on day 7, patients with moderate–severe ICANS (grade ≥ 2) had higher sNfL levels (median ‐score 2.33) than those with mild or no ICANS (median ‐score 1.72; = 0.022). The optimal cutoff to discriminate moderate–severe ICANS from other patients based on sNfL was a ‐score of 2.14 on day 7 ( = 0.004).

Discussion

Moderate–severe ICANS is associated with elevated sNfL levels by day 7 post‐infusion, indicating early neuroaxonal damage and underscoring sNfL as a valuable biomarker for assessing ICANS severity.

POSITION PAPER

Background

Post‐stroke dysphagia (PSD) is a frequent yet overlooked complication of stroke with significant implications for rehabilitation. While international guidelines provide structured recommendations for early screening and management, guidance on long‐term care remains inconsistent. This position paper synthesizes existing guidelines, identifies critical gaps, and highlights the need for standardized long‐term management strategies.

Methods

Guidelines on PSD management were identified through a two‐step approach. Fourteen guidelines were included from a previous systematic review (2014–2023), and two additional guidelines were identified through a systematic PubMed search (2014–2025). Inclusion criteria mandated guidelines of moderate‐to‐high quality (AGREE II assessment) that were published in peer‐reviewed journals and provided specific recommendations for managing PSD during acute, subacute, and chronic phases.

Results

Analysis of 10 moderate‐to‐high quality guidelines revealed strong consensus on acute‐phase screening and early interventions. All recommend dysphagia screening within 24 h of admission, with nine advising nil‐per‐os status until screening completion. There is consensus on instrumental assessments (videofluoroscopy, endoscopy), though application criteria vary. Management strategies include dietary modifications, nutritional support, oral health care, behavioral interventions, neurostimulation, and pharmacological therapies. While acute‐phase recommendations are well defined, structured long‐term follow‐up guidance remains limited, with only one guideline specifying reassessment intervals beyond hospital discharge.

Conclusion

The absence of standardized long‐term PSD management likely reflects limited availability of high‐quality evidence on long‐term care. Further research is needed to establish optimal reassessment intervals, high‐risk subgroups, and long‐term rehabilitation strategies to improve care for stroke survivors with persistent dysphagia.

CASE REPORT

Background and Aims

Guillain–Barré Syndrome (GBS) is an autoimmune disease that can cause flaccid tetraplegia. Efgartigimod, a monoclonal antibody that inhibits the neonatal receptor (FcRn), increases IgG degradation.

Methods

A 60‐year‐old lady was admitted with acute flaccid tetraparesis, requiring mechanical ventilation within 12 h. Nerve conduction studies were compatible with acute inflammatory demyelinating polyneuropathy (AIDP). No anti‐ganglioside or anti‐nodal/paranodal antibody could be identified in serum. Despite receiving standard treatment with plasma exchange (PLEX), the patient remained severely tetraparetic, bedridden, and mechanically ventilated. Human immunoglobulin 2 g/kg was given, without obtaining significant improvement. One month after disease onset, the patient received efgartigimod (10 mg/kg intravenously) weekly for four doses.

Results

We report the results of this treatment on muscle strength, patient disability, and nerve conduction studies. The tolerability profile was satisfactory, and the patient was able to walk alone after 4 months from disease onset.

Interpretation

The potential role of efgartigmod in GBS should be explored in future clinical trials.

REVIEW ARTICLE

Background

Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction (NMJ), driven by T cells, mediated by B cells, and dependent on autoantibodies. In addition to the typical motor symptoms of fluctuating weakness, the non‐motor symptoms are also prevalent among MG patients. This review aims to present the non‐motor symptoms of MG and their potential pathogenesis, hoping to contribute to personalized diagnosis and treatment.

Methods

This review elaborates the non‐motor symptoms of MG and systematically detail, for the first time, their potential pathogenic mechanisms, offering a new perspective for clinical evaluation.

Results

The non‐motor symptoms of MG include autonomic disorders (urinary, gastrointestinal, cardiovascular and ocular dysfunction), sensory disability (olfactory abnormalities, gustatory reduction and headaches), cognitive impairment, sleep disturbances, psychological problems (depression and anxiety), and TAMG‐associated specific syndromes. Due to their insidious onset and lack of awareness, these symptoms are often overlooked. We review the non‐motor symptoms of MG and first provide a systematic and detailed discussion on their potential mechanisms, including the influence of MG‐specific antibodies (cross‐reactivity of AChR‐Ab, expression of MuSK‐Ab, and striational antibodies at related functional sites), dysregulation of inflammatory factors and immune cells, collateral effects of motor symptoms, impacts of MG comorbidities, and paraneoplastic syndromes caused by thymoma.

Conclusion

Non‐motor symptoms are common in MG patients. Given a series of potential mechanisms probably involved exploring these non‐motor symptoms will not only enhance our understanding of MG but also aid in diagnosis and the development of precise, personalized treatments, ultimately improving the overall life quality of patients.

ORIGINAL ARTICLE

Background

The myeloid differentiation primary response 88 (MYD88) protein is involved in immune processes through the activation of the toll‐like receptors and the interleukin‐1 receptor. The acquired MYD88 mutation enhances its activity and promotes inflammatory pathways and autoimmune diseases. Our aim was to determine the frequency of the MYD88 mutation in chronic inflammatory demyelinating polyradiculoneuropathies (CIDP) and multifocal motor neuropathy with conduction blocks (MMN) and to assess its potential effect on the phenotype of the neuropathy.

Methods

The MYD88 mutation was tested in the peripheral blood mononuclear cells of 79 CIDP, 35 MMN, and 57 controls with nonimmune mediated disorders. Disease severity was assessed on disability scores, neurofilament light chain dosages, motor unit counts, and sums of the sensory and motor amplitudes on electrodiagnostic tests.

Results

The MYD88 mutation was more frequent in MMN patients (12/35, 34%; odds ratio 28 [95% confidence interval 4–1262];  < 0.001) and in CIDP patients (15/79, 19%; OR 13 [95% confidence interval 2–561];  < 0.001) than in controls (1/57, 2%). Patients with the MYD88 mutation were more likely to have an IgM monoclonal gammopathy (13/27 vs. 8/87,  = 0.001). The MYD88 mutation remains more frequent in CIDP and MMN patients, even if patients with IgM monoclonal gammopathy were excluded. All the other characteristics were similar, especially the severity of the disease and the efficacy of intravenous immunoglobulins.

Conclusions

The MYD88 mutation is frequent in CIDP and MMN patients, suggesting new pathophysiological hypotheses and new therapeutic approaches.

SHORT COMMUNICATION

Objective

Conflicting findings have been reported on the association between military service and the risk of motor neuron disease (MND) whereas the clinical characteristics of MND patients with previous military service have rarely been described.

Methods

We conducted a nationwide nested case–control study, including 1452 incident cases of MND diagnosed during 2015–2023 according to the Swedish MND Quality Registry and 7276 age‐ and sex‐matched controls identified from the Swedish Total Population Register. Conditional logistic regression was used to assess the risk of MND in relation to previous military service. We also described the clinical characteristics of MND patients with military service.

Results

Ten MND patients (0.7%) and 62 controls (0.9%) had previous military service. No association was found between military service and future risk of MND (OR = 0.71; 95% CI: 0.36–1.40). Compared with other patients, MND patients with previous military service appeared to have a lower age at diagnosis, a higher prevalence of non‐bulbar onset, as well as a longer survival.

Conclusions

Military service was not associated with the risk of MND. MND patients with military service appeared to demonstrate a different phenotype compared to other MND patients.

ORIGINAL ARTICLE

Objective

Prognostication of neurological outcome in critically ill patients presents significant challenges. While EEG reactivity may be associated with outcome in hypoxic–ischemic brain injury (HIBI), it has received scarce attention in other etiological conditions. Our objective was to investigate the association of EEG reactivity to clinical outcome in patients with disorders of consciousness of various etiologies.

Method

This is an ancillary study of the randomized CERTA trial (NCT03129438), which included adults with disorders of consciousness randomized to continuous EEG for 30–48 h or two routine EEGs (20–30 min). We explored the association between EEG characteristics and neurological outcome at 6 months, a modified Rankin Scale (mRS) 3–6 being considered unfavorable.

Results

A total of 364 patients were included. Among them, 112 patients had HIBI, 85 intracranial hemorrhage (ICH), 28 ischemic stroke, 48 traumatic brain injury (TBI), 23 toxic‐metabolic encephalopathy, 7 encephalitis, and 114 had unknown or other etiologies. In the overall cohort, abnormal background continuity (OR 2.33, 95% CI [1.15–4.76],  = 0.019), ictal–interictal continuum features (OR 2.78, 95% CI [1.16–6.67],  = 0.021) and unreactive background (OR 10.9, 95% CI [1.97–58.82],  = 0.006) were independently associated with unfavorable outcome. In the overall cohort, unreactive EEG had specificity of 97.3% (95% CI [94.3–100]) and sensitivity of 22.1% (95% CI [17–27.2]) for unfavorable outcome. In HIBI, specificity was 97% (95% CI [91.1–100]) and sensitivity 46.8% (95% CI [35.8–57.8]); in ICH, specificity was 94.1% (95% CI [83–100]) and sensitivity 8.8% (95% CI [2.05–15.55]); in TBI, specificity was 94.1% (95% CI [83–100]) and sensitivity 22.6% (95% CI [7.8–37.3]).

Conclusion

In this etiologically mixed cohort of critically ill adults, unreactive EEG predicted unfavorable outcome at 6 months with high specificity. EEG reactivity may reduce prognostic uncertainty not only for patients with HIBI, but also for other types of acute brain injury, such as TBI and ICH.

ORIGINAL ARTICLE

Background

Autosomal recessive mutations in the gene cause Charcot–Marie‐Tooth type 4C (CMT4C) demyelinating peripheral neuropathy.

Methods

In this nationwide observational retrospective study involving 27 French University Hospitals, we analyzed the clinical, electrophysiological, and genetic features of 103 patients from 89 families with homozygous and compound heterozygous gene mutations identified between 2003 and 2023.

Results

Mean age was 42 years (2–80), and 49% of patients were female. Mean age at disease onset was 14 years (0–52), 60% of patients started the disease before age 10 years, and 24% after age 20 years. Patients presented with distal motor weakness (93% of cases), sensory loss (86%), foot deformities (83%), scoliosis (73%), proximal limb weakness (40%), cranial nerve involvement (48%), hearing loss (37%), scoliosis‐related respiratory insufficiency (14%), and genitourinary disorders (6%). Half the patients (48%) walked independently before age 50 years, in contrast with only 13% after age 50 years. After age 50 years, 23% of patients were wheelchair‐bound. Nerve conduction studies showed sensorimotor abnormalities within the demyelinating range in all cases. We identified 56 different pathogenic variants in the gene, including 22 previously undescribed. Patients with two gene truncating variants had more severe symptoms than patients with one or zero truncating variants.

Interpretation

This study shows CMT4C is a severe childhood‐ and adult‐onset demyelinating peripheral neuropathy often associated with scoliosis, hearing loss, and ambulation loss in a significant proportion of patients after age 50 years. Genotype–phenotype correlations suggest two truncating gene variants cause a more severe phenotype.

ORIGINAL ARTICLE

Introduction

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurological disease usually described in adults. Expanded CAG repeats in the gene can lead to pediatric onset. This study aims to describe the natural history of SCA2 in children.

Methods

We analyzed clinical and genetic data from 22 children with SCA2 across 17 institutions and compared them to 20 previously reported cases.

Results

The phenotype of pediatric SCA2 can be divided into two distinct groups based on CAG repeat size and age. In the infantile group ( = 9), developmental delay and seizures were prominent features, along with cerebellar and cerebral atrophy. In the juvenile group ( = 13), the disease was a cerebellar degeneration similar to adults. A threshold of 88 ± 4 CAG repeats distinguished the infantile group from the juvenile group. Pediatric SCA2 type was independent of parental origin; SCA2 was maternally inherited in 22%, including three infantile presentations.

Discussion

This large cohort of pediatric SCA2 disease provides the first comprehensive description of its characteristics, which differ from those of SCA7. Indeed, the phenotypic spectrum of SCA7 in children is continuous, while that of SCA2 is bimodal. Although pediatric SCA2 can be difficult to diagnose by genome‐wide sequencing, it is a recognizable disease that can be easily diagnosed with a targeted study of the number of CAGs in . Genetic counseling for families should consider the significant proportion of maternal transmission.

EDITORIAL

Thrombolysis After Thrombectomy? Revisiting Intra‐Arterial Therapy in the EVT Era

ORIGINAL ARTICLE

Background

Hematoma location may influence hematoma volume and risk of expansion, the strongest prognostic predictors in patients with intracerebral hemorrhage (ICH). This study aims to determine differences in imaging and clinical factors affecting survival in patients with lobar vs. deep ICH.

Method

Patients with spontaneous supratentorial ICH residing in Skåne county registered in the Swedish Stroke Register 2016–2020 were included. Baseline non‐contrast CT scans were evaluated for hematoma location and volume, subarachnoid or intraventricular extension, hydrocephalus, and midline shift. Multivariable Cox‐ and logistic regression analyses were used to determine imaging and clinical factors associated with increased 90‐day mortality rate and functional dependency (mRS 3–5).

Results

Of 1398 patients, 666 (48%) had lobar, and 732 (52%) had deep ICH. Lobar ICH volumes were larger (median 27 vs. 13 mL,  < 0.001) compared to deep ICH. At 90 days, the unadjusted mortality rate (34% vs. 32%;  = 0.33) and functional dependency (mRS 3–5: 60.4% vs. 62.4%;  = 0.52) were non‐significant between deep and lobar ICH patients. In multivariable analysis adjusted for confounders, hematoma volume (≥ 80 mL (HR = 5.90; 95% CI: 3.40–10.23), 30–79 mL (HR = 4.24; 95% CI: 2.81–6.42), and 10–29 mL (HR = 2.21; 95% CI: 1.49–3.27)), deep ICH location (HR = 1.78, 95% CI: 1.39–2.29), hydrocephalus (HR = 1.69, 95% CI: 1.21–2.37), pre‐stroke dependency (HR = 1.51, 95% CI: 1.18–1.94), antiplatelets at onset (HR = 1.47, 95% CI: 1.14–1.90), and age (HR =1.03, 95% CI: 1.02–1.04) were significantly associated with an increased 90‐day mortality rate.

Conclusion

Despite larger hematoma volumes and older age in lobar ICH patients, lobar hemorrhages were associated with a lower mortality rate compared to deep hemorrhages. Our findings highlight the need to consider lobar and deep ICH separately in therapeutic and prognostic studies.

ORIGINAL ARTICLE

Background

Pupillary function is frequently impaired in autonomic disorders, and biomarkers for early diagnosis and disease progression are urgently needed. Pupillometry allows for noninvasive ocular autonomic evaluation. This prospective study technically and clinically validates a handheld monocular pupillometer available for broad application as an autonomic screening tool in autonomic disorders.

Methods

A total of 40 controls and 100 patients with autonomic disorders underwent pupillometry using the PLR‐4000(NeurOptics). Pupillary parasympathetic and sympathetic function were assessed by responses to a light stimulus and to 0.5% apraclonidine eye drops, respectively. Test–retest assessments and validations against a binocular device were performed.

Results

In healthy controls, the mean light reflex ratio was 42% ± 5.7% and the median response to apraclonidine was −5.0% (−8.8%–2.8%). Monocular and binocular pupillometers presented similar results. Test–retest experiments showed: median light response difference 3.0% (1.0%–4.8%), median % difference in response to apraclonidine 5.2% (2.2%–10.6%). In patients with neurodegenerative disorders ( = 24), autonomic neuropathies ( = 39), and autonomic ganglionopathies ( = 9), pupillary abnormalities were very prevalent (52%, 45%, and 100%, respectively). All patients with intermittent autonomic disorders had normal pupillomotor function.

Conclusions

The presented device provides accurate, reproducible assessments of pupillary autonomic function in healthy controls and patients with autonomic disorders. With normative data provided, it is an easily accessible, well‐tolerated tool to quantitatively assess pupillomotor innervation in a broad clinical setting. Further studies are warranted to explore its potential as a noninvasive biomarker, complementing standard autonomic function tests for early detection, monitoring disease progression, and evaluating treatment response in disorders with autonomic failure.

ORIGINAL ARTICLE

Background and Purpose

Small fiber neuropathy (SFN), resulting from dysfunction and loss of peripheral unmyelinated and thinly myelinated nerve fibers, is traditionally characterized by distal skin pain and sensory loss. Patients often report additional symptoms, including muscle cramps, myalgias, fatigue, subjective weakness, and neuropathic itch, but the prevalence and intensity of these symptoms remain poorly defined. Current treatments—focused primarily on pain—are often ineffective, possibly due to substantial between‐patient heterogeneity. This study aimed to characterize the symptomatic variability of SFN and determine whether patients can be stratified into clinically meaningful subgroups.

Methods

Demographic, clinical, and laboratory data were analyzed from patients with skin biopsy‐confirmed SFN ( = 203) and healthy controls ( = 30). SFN patients were clustered based on clinical features using unsupervised machine learning.

Results

Fatigue—not neuropathic pain—was the most prevalent and intense symptom among patients with SFN. Muscle symptoms were as common and severe as neuropathic pain, while neuropathic itch was rare. Three distinct phenotypic clusters were identified: (1) an “algesic” group (~20%) with severe neuropathic pain and co‐occurring intense symptoms; (2) a “myalgic” group (~60%) with prominent fatigue, myalgias, and subjective weakness but milder neuropathic pain; and (3) a “pauci‐symptomatic” group with few, mild to moderate symptoms. Clusters differed by symptom profiles, disease duration, intraepidermal nerve fiber density, sex, and body mass index.

Conclusion

Fatigue and muscle symptoms are highly prevalent in SFN and may rival pain in clinical importance. Identifying patient subgroups provides a foundation for stratified treatment approaches and improved disease management.

ORIGINAL ARTICLE

Background

Neurodevelopmental disorders (NDDs) may influence the course of Alzheimer's disease (AD) and frontotemporal dementia (FTD). However, prior studies have focused on specific pairs of NDDs and variants of AD/FTD. Adopting a dimensional approach to NDDs and considering the heterogeneity of AD/FTD, we investigated the association between a neurodevelopmental vulnerability (DV) and the clinical presentation and age at onset of AD/FTD.

Methods

We prospectively and consecutively recruited 84 AD/FTD participants and 41 matched controls. AD/FTD participants were classified into typical (amnestic AD, behavioral FTD) and atypical (primary progressive aphasia, frontal and posterior variants of AD, right temporal variant of FTD, amnestic FTD) presentations. Participants underwent a neuropsychological assessment and answered a novel questionnaire on NDDs symptoms. Using k‐means clustering based on the questionnaire, participants were assigned to a DV+ (with neurodevelopmental vulnerability) or a DV− (without) cluster. This data‐driven approach enabled an unbiased classification of individuals with a DV, beyond traditional diagnostic labels.

Results

DV frequencies did not differ between the AD/FTD (18%) and control (15%) χ = 0.205;  = 0.651); and between typical (21%) and atypical (11%) subgroups (Fisher's test,  = 0.184). However, in DV+ patients, symptom onset occurred 8.0 years earlier than in DV− patients (95% CI [−14, −3.0];  = 0.005), with a median onset age of 58 years (IQR: 15).

Conclusions

A DV could favor early‐onset AD/FTD, but may not affect susceptibility to typical and atypical variants of AD/FTD. The underlying neurophysiological processes involved require future investigation, with implications for precision medicine and individualized treatment strategies.

Study Registration Numbers

RnIPH 2023‐71 and Research Ethics Committee file No. 2023_765.

ORIGINAL ARTICLE

Background

The diagnosis of Varicella‐zoster virus related neurological disease (VZD) and Lyme neuroborreliosis (LNB) is based on clinical presentation as well as cerebrospinal fluid (CSF) results.

Objectives

To evaluate and compare the diagnostic utility of oligoclonal bands (OCB) and the κ‐free light chain (FLC) index in patients with VZD and LNB.

Methods

Patients with the diagnosis of VZD or LNB at the Department of Neurology of the Medical University of Innsbruck between 2008 to 2020 were included. OCB were determined by isoelectric focusing followed by immunoblotting, κ‐FLC were measured by immunonephelometry.

Results

A total of 82 patients were included in the study comprising 48 patients with VZD and 34 with LNB. LNB patients exhibited higher κ‐FLC indices (29 [14–45] vs. 4 [2–12],  < 0.001) and were more frequently OCB positive (65% vs. 8%,  < 0.001) than VZD patients. The disease duration was longer in OCB‐positive patients (VZD: 21 [18–28] days; LNB: 15 [7–22] days) compared to OCB‐negative patients (VZD: 10 [5–17] days,  = 0.030; LNB: 5 [4–7] days,  = 0.006). No differences in disease duration were observed between patients with positive or negative κ‐FLC index. In multivariable analysis, OCB positivity was associated with disease duration (Odds Ratio [OR]: 1.11, 95% confidence interval: 1.01–1.23,  = 0.028), while κ‐FLC index was not.

Conclusions

In both VZD and LNB, the κ‐FLC index was more frequently positive than OCB, particularly in cases with shorter disease duration. This suggests that the κ‐FLC index may be a more sensitive marker of (sub)acute intrathecal inflammation.

ORIGINAL ARTICLE

Background

Epileptic disorders are a heterogeneous group of neurological conditions, with many cases linked to monogenic causes, particularly in developmental and epileptic encephalopathies (DEE). Identifying pathogenic variants aids treatment, prognosis, and family planning. In France, genetic testing is coordinated through the EpiGene network.

Methods

We analyzed clinical and genetic data from 2563 epilepsy patients referred to four diagnostic labs (2016–2023). Epilepsy syndromes were classified via pre‐test questionnaires, and genotyping used various gene panels, including a 68‐gene core panel. Multivariate logistic regression assessed diagnostic rates and genotype–phenotype correlations.

Results

Overall, 27.0% of patients had pathogenic/likely pathogenic variants, mainly within the core panel (24%). and were the most frequently mutated genes. Diagnostic yield varied by syndrome, with Dravet Syndrome Spectrum (DSS) and early‐infantile DEE (EIDEE) showing the highest rates (41% and 34%, respectively). Genetic heterogeneity differed across syndromes, from DSS (predominantly ) to Infantile Epileptic Spasms Syndrome (IESS, 12%), involving ≥ 26 genes. Outside DEE, self‐limited neonatal epilepsy (SeLNE) had the highest yield (50%). Earlier seizure onset was associated with a higher likelihood of a positive molecular diagnosis, whereas intellectual disability severity and drug resistance were not independently predictive of diagnostic outcome. Genotype–phenotype correlations highlighted that objective clinical data (e.g., age of onset) can outperform syndrome labels (e.g., EIDEE) in predicting diagnosis.

Conclusion

This large cohort study refines the genetic landscape of epilepsy, informs classification challenges, and enhances genetic testing strategies, ultimately improving patient care and future research directions.

ORIGINAL ARTICLE

Background and Objectives

Transcranial sonography (TCS)‐detected substantia nigra hyperechogenicity (SN+) is a potential biomarker for Parkinson's disease (PD). While SN+ may indicate PD risk in essential tremor (ET), longitudinal undetermined tremor (UT) data are lacking; insufficient cross‐cohort validation hinders clinical translation. This study aimed to evaluate the predictive efficacy of SN+ for 8‐year PD risk and its subtype‐specific differences in ET/UT populations.

Methods

180 patients with tremors who underwent TCS were enrolled and categorized based on the tremor type (ET/UT) and SN echogenicity grade (SN+/SN−). 127 patients (59 with ET, 68 with UT) completed a mean follow‐up period of 8.01 years (range: 7.41–8.67; median: 7.92), during which new‐onset PD was documented.

Results

In the ET cohort, 52.4% of SN+ individuals developed PD, compared to 7.9% in the SN− group. For UT, the PD incidence was 91.2% in SN+ individuals and 50.0% in SN− individuals. Multivariable‐adjusted Firth logistic regression revealed significant associations between SN+ and PD in the ET and UT groups. Moreover, Bayesian logistic regression confirmed SN+ was significantly associated with PD risk in both groups. The posterior probability of an odds ratio exceeding 5 for SN+ was greater than 80% in both cohorts. Subgroup interaction analysis demonstrated no evidence of effect modification by tremor subtype, indicating consistent SN+ effects across cohorts.

Conclusions

TCS‐detected SN+ is a predictor of PD progression over 8 years in both ET and UT cohorts. The consistent risk association across tremor subtypes in SN+ subgroups supports its clinical potential as a cross‐tremor subtype biomarker.

ORIGINAL ARTICLE

Objective

This study, designed by the Greek Research Alliance for Studying headache and Pain (GRASP), aimed to (i) prospectively evaluate the effects of treatment cessation in fremanezumab‐responsive patients after 2 years exposure and (ii) assess variations in response rates after migraine worsening and treatment re‐initiation.

Methods

We analyzed 149 patients with high‐frequency episodic (HFEM) or chronic migraine (CM), who completed 24 months of fremanezumab, and mandatorily paused fremanezumab and re‐initiated it after their migraine worsened. To assess longitudinal variations mostly in monthly migraine/headache days (MMD/MHD) and other efficacy variables, patients were interviewed at baseline (T0), at month 3 (T1), month 24 (T2), treatment pause period (T3), and at month 3 after fremanezumab re‐initiation (T4). The primary objective was to assess the ≥ 50% and ≥ 75% response rates at T4, compared to T3 and T2.

Results

Migraine relapsed in previous responders at T3, while fremanezumab re‐initiation was not equally effective, as evidenced by lower ≥ 50% response rates, mostly in CM. At T4, 6 (9.7%) previously responsive HFEM patients and 27 (31%) previously responsive CM patients failed to obtain ≥ 50% MMD/MHD reduction, compared to T3. The rate of both HFEM and CM super‐responders, obtaining a ≥ 75% response at T3, also dropped at T4.

Conclusion

Discontinuation of fremanezumab after month 24 leads to rising MMD/MHDs. After fremanezumab re‐initiation, a relatively reduced effectiveness in the first 3 months might occur, compared with the pre‐fremanezumab cessation. Overall, our findings doubt the rationale behind mandated anti‐CGRP treatment pauses in migraine prophylaxis.

ORIGINAL ARTICLE

Background

Erenumab‐induced medication overuse headache (MOH) remission in participants with chronic migraine (CM) in a prospective, Phase 4, randomized, placebo‐controlled trial with an open‐label treatment period (OLTP). We present 1‐year results from the combined double‐blind treatment period (DBTP) and OLTP for the stratified nonopioid cohort.

Methods

Participants with CM‐MOH were randomized 1:1:1 to subcutaneous 70 or 140 mg erenumab every 4 weeks (QM) or placebo for the initial 24 weeks (DBTP). Those successfully completing DBTP could continue the 28‐week OLTP, maintaining the same erenumab dose received during DBTP or, if receiving placebo, randomly assigned 1:1 to erenumab 70 or 140 mg QM. OLTP endpoints were exploratory.

Results

Overall, 552 participants received erenumab (70 mg,  = 274; 140 mg,  = 278); 95.3% completed OLTP. One‐year MOH relapse in participants who achieved MOH remission at DBTP Month 6 was 2.7% (3/111) and 2.4% (3/124) with erenumab 70 and 140 mg, respectively; absence of MOH at study end was observed in 69.0% (189/274) and 75.5% (210/278) of participants. Sustained MOH absence over 1 year was reported in 60.5% (107/177) and 68.8% (119/173) of participants, respectively. Sustained improvements in measures of headache days, medication days, and function were observed in both groups. No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]).

Conclusions

Erenumab was effective in inducing and sustaining MOH remission and improving function over 1 year. Treatment compliance remained high, with safety events consistent with erenumab's known safety profile.

Trial Registration

NCT03971071

REVIEW ARTICLE

Background

No comparative evaluations of anti‐dyskinetic drugs to mitigate levodopa‐induced dyskinesia (LID) and OFF time have been performed; head‐to‐head anti‐dyskinetic trials are unlikely to be funded. We sought to compare the efficacy, tolerability, and safety of 12 anti‐dyskinetic drugs for peak‐dose dyskinesia and OFF time through a Bayesian network meta‐analysis.

Methods

A network meta‐analysis (NMA) was conducted for randomized controlled trials (RCTs) searched through the databases of MEDLINE, Embase, Cochrane Controlled Register of Controlled Trials from incipiency to January 2025. The main endpoints were the Unified Dyskinesia Rating Scale (UDysRS), modified Abnormal Involuntary Movement Scale, or the Unified Parkinson's Disease Rating Scale IV score for LID and the number of hours of OFF time in a standardized OFF–ON diary for OFF time reduction.

Results

Twenty‐one RCTs were included in the analysis. The surface under the cumulative ranking curve (SUCRA) indicated that amantadine extended‐release (ER) was associated with the largest improvement in the UDysRS (0.934), followed by amantadine immediate‐release (IR) (0.680). For OFF time reduction, amantadine IR (0.902) and amantadine ER (0.833) were the two best treatments compared with foliglurax (0.526), mavoglurant (0.464) and sarizotan (0.012). Fipamezole ranked first in overall withdrawals (0.812). Amantadine ER ranked first in withdrawals due to adverse events (AEs) and the incidences of AEs (≥ 1 AEs) (0.900 and 0.887).

Conclusions

Amantadine ER improved dyskinesia significantly versus amantadine IR. Both formulations of amantadine were superior as OFF time‐reducing agents compared to other anti‐dyskinetic drugs, whereas amantadine IR non‐significantly reduced OFF time versus amantadine ER.

ORIGINAL ARTICLE

Background

7 Tesla (7 T) magnetic resonance imaging (MRI) offers higher spatial resolution and signal‐to‐noise ratio, enhancing visualization of multiple sclerosis (MS) lesions, including cortical and deep gray matter lesions. It improves detection of MS biomarkers like paramagnetic rim lesions (PRLs) and central vein sign (CVS). Costs have impacted its adoption and experience in clinical practice.

Objectives

To present real‐life data on the routine clinical use of 7 T MRI and its impact on patient management from a single‐center perspective.

Methods

This retrospective study, approved by the local ethics committee (KEK Bern No 2020–02902), analyzed referrals for 7 T MRI (06/2020–06/2024) at University Hospital Bern for suspected CNS inflammatory disorders. Imaging reports were compared to clinical data from medical records. Statistical analysis evaluated the diagnostic value of 7 T MRI, focusing on sensitivity, specificity, Negative Predictive Value (NPV), and Positive Predictive Value (PPV). Exclusions included contraindications for 7 T MRI, incomplete medical records, or non‐CNS conditions.

Findings

61 patients underwent 7 T MRI, enabling lesion reclassification and MS diagnosis in 19/47 patients with indefinite diagnosis despite extensive diagnostic workup with adequate 3 T MRI. In 14 MS patients, it clarified diagnostic uncertainties, leading to diagnosis revision in 1/14 patients and informed treatment decisions in 4/14 (including treatment escalation (3/14) and discontinuation (1/14)). 7 T MRI showed 89.5% sensitivity and 78.6% specificity for MS (PPV 73.9%, NPV 91.7%). MS patients were more likely to exhibit CVS and PRLs compared to non‐MS patients ( < 0.05).

Interpretation

7 T MRI enhances MS diagnosis certainty in diagnostically challenging cases, potentially impacting clinical practice.

LETTER TO THE EDITOR

Stress Hyperglycemia Ratio as a Predictor of Parkinson's Disease: Statistical Caveats Matter

ORIGINAL ARTICLE

Background

Peripheral neuropathies encompass a diverse group of disorders involving peripheral nerve damage, often leading to pain, sensory disturbances, and motor impairments. The etiology is multifactorial, with trauma as a key contributor. The treatment of peripheral neuropathies includes medications targeting the nociceptive component, whereas the neuropathic component is managed with agents such as gabapentinoids or antidepressants, though their prolonged use is limited by significant side effects. Some neuroprotective compounds, such as acetyl‐L‐carnitine (ALC), palmitoylethanolamide (PEA), and alpha‐lipoic acid (ALA), have emerged as potential alternatives due to their anti‐inflammatory and analgesic properties.

Methods

This monocentric, observational, single‐arm longitudinal study evaluated the efficacy of a fixed combination containing ALC, PEA, and ALA (as an adjuvant to the previous two) and , Vitamin E, and Vitamin B6 in patients with acute low back trauma. Over 8 weeks, 48 participants received the supplement alongside conventional therapy. The primary end point was improvement in neuropathic pain assessed via the Neuropathic Pain Scale (NPS) and Visual Analogue Scale (VAS). Secondary endpoints included quality of life (SF‐36) changes, reduced NSAID consumption, and adverse events.

Results

The study showed significant reductions in NPS and VAS scores and improvements in physical health‐related SF‐36 domains, with reduced NSAID consumption. Participants with more severe baseline symptoms demonstrated the greatest benefits. No significant changes were observed in emotional parameters. Adverse events were mild and in a very limited number of patients.

Conclusions

Results suggest the combination's potential to improve pain and reduce reliance on conventional therapies; however, further controlled randomized trials are needed to validate these findings.

ORIGINAL ARTICLE

Introduction/Aim

Grip strength (GS) is widely used in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Current guidelines recommend a 10% relative change as the minimal clinically important difference (MCID) to determine response to treatment, preferably based on the average of three consecutive daily measurements. However, appropriate thresholds remain unclear for identifying deterioration and for situations where daily monitoring is not feasible.

Methods

We analyzed 350 GS assessments from 122 CIDP patients across 2 neuromuscular centers in Korea and the UK. Clinical changes were classified as improved, deteriorated, or stable based on the patient's perception of change and validated outcome measures: Inflammatory Neuropathy Cause and Treatment (Korea), Overall Neuropathy Limitation Scale (UK), and Inflammatory Rasch‐built Overall Disability Scale (both sites). The Youden index was used to determine optimal MCID thresholds for absolute (kg) and relative (%) changes for improvement and deterioration, respectively. The performance of derived cut‐offs was compared with previously proposed thresholds.

Results

The guideline‐recommended 10% relative threshold showed notably low specificity and accuracy despite high sensitivity for both improvement and deterioration. Our derived thresholds, 5 kg for improvement, 4.5 kg for deterioration, and 20% for either direction of change, offered significantly higher specificity and accuracy.

Conclusion

Our findings highlight the need for more stringent thresholds than current recommendations when assessing patients based on single‐day measurements. Our proposed thresholds, double in amplitude of the currently guideline‐recommended relative value but close to that previously derived for the absolute cut‐off, offer improved diagnostic specificity, which may ensure more reliable monitoring in routine care.

ORIGINAL ARTICLE

Introduction

Bell's palsy is the most common cause of peripheral facial paralysis, with an annual incidence of 5–50 per 100,000 cases worldwide. Its etiology remains largely unknown, though risk factors such as herpes simplex virus reactivation, diabetes, depression, and pregnancy‐related complications have been suggested. Understanding these risk factors is critical for improving diagnosis, prevention, and treatment strategies.

Methods

A retrospective analysis of the TriNetX database included over 25 million patients. Two cohorts of approximately 140,800 patients each, matched for age and sex, were analyzed for associations between BP and herpes simplex virus, diabetes, depression, and pregnancy. Odds ratios (OR) and confidence intervals (CI) were calculated, with  < 0.05 indicating significance.

Results

Herpes simplex virus showed the strongest association with Bell's palsy (OR: 6.49, 95% CI: 5.96–7.05); followed by diabetes (OR: 2.4, CI: 2.36–2.46) and depression (OR: 2.05, CI: 2.0–2.1). Pregnancy was inversely correlated (OR: 0.76, CI: 0.73–0.78).

Conclusion

Herpes simplex virus reactivation appears to be a major risk factor, suggesting a potential role of antiviral therapies in select cases. The associations with diabetes and depression highlight a need for metabolic and mental health evaluations in patients with Bell's palsy. The inverse correlation with pregnancy warrants further investigation into pregnancy‐related conditions. These findings emphasize the multifactorial nature of this condition and the importance of individualized approaches to reduce its idiopathic classification.

ORIGINAL ARTICLE

Background

Persistent Postural‐Perceptual Dizziness (PPPD) is a prevalent functional neuro‐otologic disorder characterised by non‐spinning vertigo, perceived instability and visual motion sensitivity. Diagnostic criteria currently prioritise physical symptoms; although psychological factors are clinically linked to symptom onset and maintenance. This study investigates psychological factors in vestibular disorders by comparing PPPD patients with healthy controls, and exploratorily, with Bilateral Vestibulopathy (BVP) patients, identifying differentiating constructs and potential treatment targets.

Methods

We conducted a cross‐sectional study of 164 participants (59 PPPD, 16 BVP, 89 healthy controls), completing questionnaires on negative illness perception, anxiety, cognitive fusion, perceived injustice, balance vigilance, visually induced dizziness (VIMSSQ), dizziness severity (NPQ) and related constructs. Logistic regression and mediation analyses assessed psychological variables mediating dizziness symptoms and differentiating PPPD from controls and BVP.

Results

Two key insights emerged. First, perceived injustice (IEQ) best differentiated PPPD from healthy controls, surpassing dizziness severity and other psychological constructs. Second, visually induced dizziness (VIMSSQ) most effectively distinguished PPPD from BVP, outperforming even the PPPD‐specific Niigata PPPD Questionnaire (NPQ). Mediation analyses indicated VIMSSQ's predictive strength depended largely on anxiety and perceived injustice.

Conclusions

Cognitive appraisals such as perceived injustice are critical constructs in PPPD symptomatology. Given limited PPPD‐specific psychometric tools addressing psychological dimensions beyond general anxiety, developing assessments sensitive to these factors is essential for evidence‐based holistic interventions.

LETTER TO THE EDITOR

Clinical Insight on “Association Between Stress Hyperglycemia Ratio and Parkinson's Disease Across Different Glucose Metabolism Statuses—A Prospective Study From UK Biobank”